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ABSTRACT 
Objective: The aim of the present study was to formulate and optimize famotidine loaded micro balloons for enhancing bioavailability, increasing 
gastric residence time of drug and to achieve sustained release in the stomach.  
Methods: Microballoons were prepared using emulsion solvent diffusion method using HPMC K4M as the polymer. All the formulated microspheres 
were subjected to various evaluation parameters such as % drug entrapment, micromeritics properties, % buoyancy and in vitro drug release 
studies. The formulation was optimized using 32 full factorial design. Optimized formulation was subjective to in vivo floating (X-ray) and in vivo 
antiulcer studies. 
Results: The microballoons were smooth and spherical in shape and were porous in nature due to hollow cavity. Sustained/controlled release of 
drug was observed for more than 12 h. based on the results of % drug entrapment, in vitro drug release and % buoyancy studies, formulation F6 
was selected as optimized formulation. The release kinetics of optimized formulation followed Higuchi model and mechanism of release was non-
Fickian diffusion. Examination of the X-ray radiographic images taken during the study indicated that the optimized formulation remained buoyant 
and uniformly distributed in the gastric contents for a long period. In ethanol-induced ulcer model, drug-loaded microballoons treated group 
showed significant ulcer protection index of 83.26% as compared to the marketed brand of famotidine 76. 09% and untreated control group. 
Conclusion: Famotidine-loaded floating micro balloons were successfully prepared and prove to be useful for the prolonged gastric residence of the 
drug, better bioavailability, patient compliance and anti-ulcer activity. 
Keywords: HPMC, Famotidine, In vitro release, Factorial design, % drug entrapment, In vivo floating 




Different types of ulcers such as duodenal ulcers, gastric ulcers, 
Zollinger-Ellision syndrome and gastroesophageal reflux disease are 
major side effects of many drugs and H2-receptor antagonists are 
used for their treatment. Famotidine is one such potent histamine 
H2-receptor antagonist with a short biological half-life (2.5-4 h). 
Famotidine is readily but incompletely absorbed with site-specific 
absorption in the upper part of the gastrointestinal tract (GIT) with 
an oral bioavailability of 43-50% due to narrow absorption window 
in GIT [1-2]. Famotidine is also stable in acidic pH and has low 
conventional dose (20-100 mg daily in divided dose) so it is able to 
allow incorporation of polymer and other formulation excipients. 
Famotidine shows site-specific action in the treatment of different 
types of ulcers thus providing drug continuously to its absorption 
sites in a controlled manner, extending absorption phase and 
increasing the magnitude of drug effect [3]. 
Therefore the development of controlled/sustained release 
formulation in the form of multiple units floating drug delivery 
system (FDDS) such as microballoons (floating microspheres) would 
be an ideal approach for oral delivery of famotidine. Microballoons 
are gastro retentive drug delivery systems based on non-
effervescent approach. Microballoons are spherical empty particles 
without core ideally having a size less than 200 micrometres. 
Microballoons float and can be retained in the stomach due to their 
lower bulk density than the gastric contents and remain buoyant in the 
stomach for a prolonged period of time without affecting the gastric 
emptying rate of other contents. Microballoons assist in improving the 
oral sustained delivery of drugs that have an absorption window in a 
particular region of the gastrointestinal tract.  
Microballoons are considered as one of the most promising buoyant 
systems, as they possess the unique advantages of multiple unit 
systems as well as better floating properties, because of central hollow 
space inside the microsphere [4-6]. The aim of present study was to 
formulate and optimize gastro-retentive microballoons of famotidine 
for increasing gastric residence time of formulation thereby giving 
controlled release of famotidine in the gastric fluid for site-specific 
treatment of peptic ulcer, increasing the magnitude of drug effect, 
improving the oral bioavailability of the drug and patient compliance. 
MATERIALS AND METHODS 
Materials 
Famotidine was obtained as gift sample from Sun Pharmaceuticals 
Pvt Ltd, Gujarat, India. Hydrochloric acid was purchased from 
qualigens fine chemicals, Mumbai, India. HPMC K4M was procured 
from Titan Biotech Ltd, India. All the ingredients used were of 
pharmaceutical grade. Solvents of reagent grade were used in all 
experiments. 
Methods 
Drug-excipient compatibility study  
Drug-excipient compatibility study was carried out to check the 
compatibility of the drug with the polymer in preparation of 
microspheres of famotidine. The drug and polymer mixture of 
quantity 10 mg and 400 mg of KBr were acquired in a mortar and 
were triturated. A little volume of the triturated sample was seized 
and kept on to the sample holder and examined from 4000 cm-1 to 
400 cm-1 in Shimadzu FTIR 8400 spectrophotometer. The spectra 
obtained were matched with that of the peaks obtained from the 
FTIR study of the pure drug sample and interpreted for the 
interaction of drug and polymers if any [7-9]. 
Preparation of famotidine loaded floating microballoons 
Floating microballoons were prepared by the emulsion solvent 
diffusion method. Nine formulations of floating microballoons were 
prepared. Different ratios of famotidine and HPMC K4M were mixed in 
a mixture of ethanol and dichloromethane (DCM) in the ratio of 2:1. 
International Journal of Applied Pharmaceutics 
ISSN- 0975-7058                                  Vol 10, Issue 3, 2018 
Chandra et al. 
Int J App Pharm, Vol 10, Issue 3, 2018, 131-140 
132 
The resulting suspension was added slowly into stirring to 0.50% 
w/v 400 ml solution of polyvinyl alcohol (PVA) at room 
temperature. The emulsion formed was stirred continuously for 2 h 
using a propeller-type agitator at different rpm (900, 1200 and 1500 
rpm). The temperature was maintained at 40°C. The finely dispersed 
droplets of the polymer solution of the drug were solidified in an 
aqueous phase via the diffusion of the solvent, leaving the cavity of 
microspheres filled with water. Microballoons formed were filtered 
using a nylon cloth and washed repeatedly with distilled water. The 
collected floating microballoons were dried at room temperature 
and stored in desiccators [10]. 
Evaluation of famotidine loaded floating microballoons 
Micrometrics properties of microballoons 
Angle of repose 
The angle of repose is the angle a pile forms with the ground. Angle 
of repose was determined using fixed funnel method. The height of 
the funnel was adjusted in such a way that the tip of the funnel just 
touches the heap of the blends. The accurately weighed blend is 
allowed to pass through the funnel freely onto the surface. The 
height and diameter of the powder cone were measured and angle of 
repose was calculated using the following equation.  
Ө = tan-1(h/r) 
 Where, h = height of pile, r = radius of pile, and θ = angle of repose  
Bulk density and tapped density  
Bulk density is defined as the mass of powder divided by the bulk 
volume. Bulk density is determined by pouring a known quantity of 
microspheres into the measuring cylinder without compacting and 
read the unsettled apparent volume.  
Bulk density is the ratio between a given mass of a microsphere and 
its bulk volume.  
Bulk Density = Mass of powder/Bulk volume of the powder 
Tapped density is determined by transferring a known quantity of 
microballoons (2 gm) into a measuring cylinder (10 ml) and is 
tapped mechanically till a constant volume is obtained. This volume 
is the bulk volume and it includes the true volume of the powder and 
the void space among the microballoons. Tapped density is 
calculated by using the formula. 
Tapped density = Weight of powder/Tapped volume of the powder 
Carr’s index 
Carr’s compressibility index CI (Carr, 1965) is defined as follows:  
Cl = pi-pa/pt = Va–Vt/Vt 
Where ρt and ρa–tapped and poured bulk density; and Vt and Va–
tapped and poured bulk volume respectively.  
Hausner’s ratio 
A similar index has been defined by Hausner [11].  
Hausner’s ratio = Tapped density/Poured density 
Determination of particle size 
The particle size of microballoons was measured by using an optical 
microscope fitted with an eyepiece micrometre and a stage 
micrometre. The mean particle size was determined by measuring 
200 particles with the help of a calibrated eyepiece micrometre [12].  
Surface morphology 
The surface characteristics and internal textures of the famotidine 
loaded floating microballoons were studied by scanning electron 
microscope. The samples were mounted on double-sided tape that 
has previously been secured on copper stubs and then analyzed at 
different magnifications. Photomicrographs were captured 
randomly using scanning electron microscope. 
Drug entrapment efficiency  
Estimation of drug entrapment efficiency (DEE) in floating 
microballoons was carried out by dissolving the weight amount (100 
mg) of crushed microballoons in required quantity of 0.1N HCl, pH 
1.20 and analyzed spectrophotometrically at a wavelength of 266 
nm using the calibration curve. The polymer debris was removed by 
filtering through Whatman filter paper (No. 40). Each batch should 
be examined in a triplet manner. The entrapment efficiency of 
floating microballoons was calculated by dividing the actual drug 
content by the theoretical drug content of microballoons [13]. The % 
DEE of floating microballoons was calculated using this following 
formula:  
 
In vitro buoyancy study  
This study was carried out by USP type II dissolution test apparatus 
by spreading the microballoons on a simulated gastric fluid (900 ml 
of 0.1 N HCl, pH 1.20) containing 0.02% w/v Tween 20 as a 
surfactant. The media is stirred at 100 rpm at 37±0.5оС for 12 h. 
After a specific interval of time, both the fractions of microballoons 
(floating and settled microballoons) were collected and buoyancy of 
the floating microballoons was determined by using formula [14]. 
 
Where Qf is the weight of floating microballoons and Qs is the weight 
of settled microballoons respectively. 
In vitro dissolution study  
The in vitro dissolution studies were carried out using USP type II 
dissolution apparatus (Paddle Type). The study was carried out in 
900 ml of 0.1N HCl (pH 1.20). The dissolution medium was kept in a 
thermostatically controlled water bath, maintained at 37±0.5°C. 
Microballoons containing drug equivalent to 40 mg were spread 
over the surface of 900 ml of dissolution media (0.1N HCl, pH 1.20). 
The paddle was rotated at 50 rpm. At predetermined time intervals 
i.e. 1, 2, 4, 6, 8, 10, 12 and 15 h 5 ml of sample was withdrawn from 
the dissolution apparatus and replaced with fresh media to maintain 
sink conditions. The drug concentration was analyzed by using UV 
spectrophotometer (Shimadzu 1800, Japan) at 266 nm [15-17]. 
Optimization and validation of experimental design 
Optimization technique based on response surface methodology was 
utilized. It is generally used to determine the optimum combination 
of factors that yield the desired response and describes the response 
near the optimum. The runs or formulations, which are designed 
based on 32full factorial designs, are evaluated for the response 
variables. The response values are subjected to multiple regression 
analysis to find out the relationship between the factors used and 
the response values obtained. Independent variables or factors 
studied were a drug: polymer ratio (X1) and stirring speed (X2). The 
response values or dependent variables subjected for this analysis 
were % entrapment efficiency, % drug release at 12 h and % 
Buoyancy. The effect of formulation variables on the response 
variables was statically evaluated by applying one-way ANOVA at 
0.05 level using a commercially available software package Design 
Expert® 10.0.3 (Stat-Ease, USA). The design was evaluated by 
polynomial cubic model, which bears the form of the following 
equation.  
Y=b0+b1X1+b2X2+b12X1X2+b12X12+b22X22+b12b2X12X2+b1b22X1X22 
Where Y, is the dependent variable; b0 is the arithmetic mean 
response of the 9 runs; and b1 and b2 are the estimated coefficients 
for the independent factors X1 and X2, respectively. The main effects 
(X1 and X2) represent the average result of changing one factor at a 
time from its low to high value. The interaction term (X1X2) shows 
how the response changes when 2 factors are simultaneously 
changed. The polynomial terms (X12 and X22) are including 
investigating nonlinearity. The student t–test was conducted to 
examine the probability of each coefficient being equal to zero. All 
tests were performed at a 95% level of significance. In the final 
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reduced model of polynomial equation, only the significant factors 
and coefficients were included. The reduced polynomial equation 
was applied to predict the theoretical responses (predicted 
responses). Once the predicted response was established, the extra 
design checkpoint formulation was formulated and evaluated to 
validate the polynomial equation model. 
The extra design checkpoint formulation (F10) was obtained from 
transformation of each of two variables at three levels. In general, 
the formula for transformation is as follow [18].  
 
The values for the variables obtained after transformation were 
incorporated into the extra design checkpoint formulation 
designated as F10. 
The model, a comparison between the experimental and predicted 
values of the responses is also presented in terms of % Bias. 
% Bias was calculated by the following equation:  
 
To demonstrate graphically the influence of each factor on responses 
and to indicate the optimum level of factors, the contour and 
response surface plots were generated using Design-Expert 10.0.3 
software, p<0.05 was considered significant. 
Drug release kinetics of optimized formulation  
In vitro drug release data of optimized formulation (F6) was 
subjected to various mathematical models such as zero order, first 
order, Higuchi and Peppas kinetics models to understand the 
mechanism from the floating microballoons of famotidine. All curve 
fitting and plotting were performed using Microsoft excel software 
and regression coefficient (r2) values were calculated. In this by 
comparing the regression coefficient (r2) values obtained, the best fit 
model was selected [19-23]. 
In vivo floating behaviour study  
Healthy rabbits weighing approximately 2 kg were used to assess in 
vivo floating behaviour. Ethical clearance for the handling of 
experimental animals was obtained from the institutional animal 
ethical committee (Registration No. 1321/PO/ReBi/S/10/CPCSEA) 
constituted for the purpose. The animals were housed in individual 
cages, and the experiments were carried out in a sanitized room. 
Rabbits fasted for 12 h and the first X-ray photograph was taken to 
ensure the absence of radio-opaque material in the stomach. Barium 
sulphate was incorporated into the microballoons to make the 
microballoons X-ray opaque. The amount of barium sulphate was 
kept 10 mg per g of microballons to ensure visibility by X-ray and to 
enable the microballoons to float. Rabbits were made to swallow 
barium sulphate loaded microballoons with sufficient quantity of 
water. During the experiment, rabbits were not allowed to eat but 
the water was provided ad libitum. At predetermined time intervals 
(0, 6 and 12 h) the radiographs of the abdomen were taken using an 
X-ray machine [24-25].  
Antiulcer activity 
Albino Wistar rats of either sex weighing between (150-200 gms) were 
used to determine antiulcer activity. Ethical clearance was obtained from 
the institutional animal ethical committee (Registration No. 
1321/PO/ReBi/S/10/CPCSEA) constituted for the purpose. Albino 
Wistar rats were housed in individual cages, and the experiments were 
carried out in a sanitized room. Albino Wistar rats were divided into four 
groups of six animals in each group. Group I served as control rats, 
administered 80% v/v ethanol (1 ml/200 gm, p. o.); Group II 
administered optimized formulation (20 mg/kg, p. o.); Group III 
administered optimized formulation modified with addition of 25 mg of 
gallic acid (20 mg/kg, p. o.) to study the effect of gallic acid (natural 
antioxidant); Group IV administered famotidine marketed drug (20 
mg/kg, p. o.). The animals fasted for 24 h with free access of water. The 
animals were treated with formulations or control according to the 
various groups as designed. 1 hour later 80% v/v alcohol was 
administered p. o. to each animal. Animals were sacrificed after 1 hour of 
alcohol administration, stomachs were isolated, cut and opened along 
the greater curvature and pinned on a soft board. Ulcer index 
parameters were studied [26, 27].  
Erosions formed on the glandular portion of the stomach were 
counted and each was given a severity rating on 1-3 scale, based on 
the diameter of the ulcer. Scoring of ulcers for normal stomach, red 
coloration, spot ulcer, hemorrhagic streak, ulcers and perforation 
were carried out as 0, 0.5, 1, 1.5, 2 and 3 respectively. 
Mean ulcer score for each animal will be expressed as ulcer index. % 
Ulcer protection can be calculated by using this formula. 
 
Calculation of ulcer index can be carried out using this formula. 
UI = (UN+US+UP) x 10-1 
UI = Ulcer index 
UN = Average of number of ulcer per animal 
US = Average of severity score 
UP = Percentage of an animal with ulcer 
The Dunnett’s test was employed for statistical comparison. In all 
the cases, values of P<0.05 were considered significant. All values 
were presented as mean±SEM. 
RESULTS AND DISCUSSION 
Drug-excipient compatibility study  
After performing FTIR of the famotidine, HPMC and microballoons, it 
was found that the peaks obtained in the formulation were in 
between the range of main principle peaks and were found to be 
very near to previously performed FTIR of pure drug famotidine. No 
major deviation in peaks was obtained in IR spectra, hence this 
indicates that drug was compatible with excipients without any 
significant interaction between famotidine and HPMC. The results of 
IR spectra suggest that selection of excipient for preparation of 
microballoons were suitable. Hence it cannot alter the therapeutic 
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Fig. 1: FTIR spectra of (a) Famotidine (b) HPMC (c) Famotidine loaded microballoons 
 
Preparation of famotidine loaded floating microballoons 
The floating famotidine loaded microballoons were prepared using 
emulsion solvent diffusion method as discussed in preparation of 
floating microballoons of famotidine. The polymer used was HPMC 
K4M and its composition was tabulated in table 1. Further, the 
stirring speed was varying from 900 to 1500 rpm. The finely 
dispersed droplets of the polymer solution of the drug were 
solidified in an aqueous phase via the diffusion of the solvent, 
leaving the cavity of microspheres filled with water. The benefits of 
preparation technique include low processing time, lack of exposure 
of drug to high temperature due to which stability of drug increased 
during the processing leading to high % entrapment efficiency of the 
drug in microballoons. 
  
Table 1: Composition of floating microballoons using 32 full factorial experimental design 
Formulations code Variable level in the coded form  
X1 X2 
F1 -1 -1 
F2 0 -1 
F3 1 -1 
F4 -1 0 
F5 0 0 
F6 1 0 
F7 -1 1 
F8 0 1 
F9 1 1 
Concentration/value of independent variables 
Level Concentration of HPMC K4M (mg) Stirring Speed (rpm) 
-1 100 900 
0 200 1200 
1 300 1500 
Response variables 
Y1 % Entrapment Efficiency 
Y2 % Drug Release in 12 h  
Y3 % Buoyancy 
 
Micromeritic properties of microballoons 
All the prepared batches of famotidine microballoons were 
evaluated for micromeritic properties such as bulk density, tapped 
density, carr’s compressibility index, hausner’s ratio and angle of 
repose as shown in table 2. 
Angle of repose 
The values for angle of repose of all prepared nine formulation batches 
were determined in the range of 22.14°±0.67 to 27.19°±0.62 showing 
that the different batches of microballoons were free-flowing with 
good flow property. In case of pure drug angle of repose was 39. 4 
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°±1.34 suggesting poor flow properties. All formulation batches 
possess smoother and regular surface of the particles.  
Bulk density  
The bulk density values for all nine formulation batches were 
determined. The result of poured bulk density (g/cm3) ranged from 
0.49±0.24 to 0.69±1.06 as shown in table 2. The bulk densities of 
different formulations were found to be much less than the density 
of the gastric fluid (1.004 g/cm3) and 0.1 N HCl, pH 1.20 (0.997 
g/cm3). Low density of microballoons increased the porosity of 
microballoons. Being less in density, the microballoons were 
expected to float immediately with less or no lag time. 
Tapped density 
The tapped density of microballoons of all nine formulation batches 
were found to be in the range of 0.55±0.58 to 0.76±0.45 g/cm3 as 
tabulated in table 2. Therefore, it was expected to be suitable for 
formulation of floating microballoons as they were having less 
density than 0.1 N HCl, pH 1.20. 
Compressibility index 
Carr's compressibility index was evaluated to determine 
compressibility characteristics of the microballoons. Carr's 
compressibility index of floating microballoons of all nine 
formulations ranged from 7.935.40±0.0009 to 13.11±0.0003 % 
indicating excellent flow properties of microspheres with good 
compressibility while in case of pure drug carr's compressibility 
index was 24.86±0.0012 % showed poor flow properties of the pure 
drug. Therefore, prepared floating microballoons showed 
improvement in flow properties as compared to pure drug and 
packability inside the capsules meant an ease of filling the 
microballoons inside the capsules. 
Hausner’s ratio 
Hausner’s ratio for all nine formulations was in the range of 1.08 
to 1.15 (<1.25) indicating good flow properties of microballoons 
while in case of a pure drug, Hausner ratio was 1.33. It suggested 
that Hausner ratio of all formulations of microballoons were less 
than pure drug and the result of the study showed enhancement 
of flow properties of the pure drug in case of floating micro-
balloons. 
Determination of particle size  
The mean particle size of all formulations was ranged from 
109.43±1.18 µm to 160.58±0.73 µm as tabulated in table 2. 
Formulation batches F7 showed smallest and F3 showed the largest 
size of microballoons. Higher particle size was obtained when the 
proportion of HPMC K4M was increased in formulations. This was 
due to a significant increase in viscosity in a fixed volume of solvent, 
thus causing an increase in emulsion drop size and finally increases 
in size of particles. Increased speed of mixing (stirring) resulted in 
the formation of small-sized microballoons. 
 

















1 F1 22.14±0.67 0.49±0.24 0.55±0.58 10.90 1.12 151.25±0.25 
2 F2 23.32±0.42 0.53±0.63 0.61±0.48 13.11 1.15 158.17±0.86  
3 F3 25.28±0.61 0.61±0.72 0.67±0.35 8.95 1.09 160.58±0.73 
4 F4 23.42±0.37 0.53±0.57 0.58±0.67 8.62 1.09 129.56±0.68  
5 F5 23.84±1.74 0.59±0.39 0.65±0.53 9.23 1.10 135.28±1.15 
6 F6 26.14±0.49 0.68±0.42 0.76±0.45 10.52 1.11 141.62±1.24 
7 F7 23.68±0.88 0.58±0.82 0.63±0.58 7.93 1.08 109.43±1.18 
8 F8 24.72±0.39 0.69±1.06 0.75±0.46 8.00 1.08 113.32±0.92 
9 F9 27.19±0.62 0.62±0.76 0.68±0.73 8.82 1.09 120.14±0.78 
* All values are expressed as mean±SD, n =3 
 
Surface morphology 
The surface morphology of famotidine loaded floating microballoons 
was investigated by SEM. It was seen that microballoons were 
spherical in appearance and exhibit a range of sizes within each 
batch. The surface was observed to be smooth, dense and less 
porous, whereas the internal core was highly porous. The less 
porous outer surface and highly porous internal surface supported 
controlled release of drug from the microballoons and good 
buoyancy. The porous nature and cavity formed in the 
microballoons would dictate the floating behaviour of famotidine 
loaded floating microballoons. 
  
   
(a)    (b)    (c) 
Fig. 2: SEM photographs of (a) range of floating microspheres (b) smooth texture of floating microspheres (c) porous internal surface of 
floating microspheres
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Drug entrapment efficiency  
The percent drug entrapment efficiency (% DEE) of all formulation 
batches were found to be in the range of 63.47±1.46% to 
70.34±0.98% as shown in fig. 2. The % drug entrapment efficiency 
was more when the concentration of polymer (HPMC K4M) was 
increased in the drug: polymer ratio. Drug encapsulation efficiency 
was found to be increased due to increase in the concentration of 
gelling polymer leading to increase in crosslinking structure and 
viscosity of internal phase which leads to reduce migration of drug 
in aqueous phase. % DEE of formulations was found to decrease 
with an increase in stirring speed from 900 to 1500 rpm due to 
smaller size microspheres formed at a higher speed of rotation and 
leakage of drug from microspheres.  
In vitro buoyancy study 
In vitro buoyancy (%) for all the formulations batches, F1 to F9 were 
varied from 64.17±1.16% to 83.21±1.07%. It was observed that all 
the formulations were able to remain float in a continuous manner 
on the dissolution medium over a period of 12 h. The in vitro 
buoyancy of hollow microspheres of famotidine was due to the 
presence of pores, a hollow structure and low bulk density. It may 
also deduce that these microballoons can float in gastric fluid 
retarding the passage of the microballoons into the intestinal region 
and increasing their residing time in the stomach. The in vitro % 
buoyancy was found to increase with increasing concentration of 




Fig. 3: Comparative chart of % encapsulation efficiency and % buoyancy of different formulations 
 
In vitro dissolution study 
In vitro drug release of famotidine from microballoons was 
performed in 0.1 N HCl, pH 1.20. The in vitro release profile showed 
initial burst release up to 1 h which may be due to the surface 
associated drug, followed by a sustained release phase as the 
entrapped drug slowly diffused into the dissolution medium. There 
was the sustained release of drug at a constant rate. The results of 
the study showed that on increasing the concentration of HPMC K4M 
it decreased drug release from microballoons. The high 
concentration of HPMC K4M decreases the drug release from 
microballoons due to more stiffness of microballoons and increased 
diffusional path length. The other reason may be that smaller 
microballoons were formed at lower concentrations of HPMC K4M 
and have a large surface area exposed to the dissolution medium 
resulting in faster drug release. Higher stirring speed also lead to 
increase in drug release due to the breakdown of microballoons into 
small pieces or rupturing the surface of microballoons. Formulations 




(a)      (b) 
Fig. 4: In vitro drug release profile of floating microballoons for (a). F1 to F5 (b). F6 to F9 
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Optimization and validation of experimental design 
The nine formulations of microspheres were prepared to study the 
effect of polymer concentration and speed of stirring speed. 
The effect of formulation variables on the response variables was 
statically evaluated by applying ANOVA at 0.05 level using a 
commercially available software package Design Expert® 10.0.3 
(Stat-Ease, USA). Mathematical polynomial cubic equations were 
generated for all the three dependent variables or response 
parameters such as % entrapment efficiency, % drug release at 12 h 
and % Buoyancy. The mathematical models were tested for 
significance. The response values are subjected to multiple 
regression analysis to find out the relationship between the factors 
used and the response value obtained.  
As there were insignificant terms, the model reduction was required. 
After reduction, reduce cubic model was used and thus the data 
points were better fitted with the model and all the response models 
were significant with the response parameters. It was found that 
quadratic model is best fitted to determine the effect of independent 
variables on response variables. 
The quadratic equations generated for responses were given as 
% EE=+68.52+0.54X1-1.08X2-2.39X1X2-0.77X12-1.72X22 
% Drug release=+86.38-2.61X1+3.15X2 
% Buoyancy=+73.41+7.31X1-2.32X2 
Where X1 and X2 represent the coded values of the polymer 
concentration and stirring speed (rpm) respectively. The positive 
value of a factor in the above equations points outs the enhancement 
of that response and vice versa. 
To demonstrate graphically the influence of each factor on responses 
and to indicate the optimum level of factors, the contour and response 








Fig. 5: Response surface and contour plot of effect of X1 and X2 on (a). % entrapment efficiency (b). % drug release at 12 h (c) % buoyancy 
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By calculating actual polymer concentration (225 mg) and stirring 
speed (1275 rpm) from transformed proportions of each variable, 
the extra design checkpoint formulation (F10) was designed.  
The extra design checkpoint batch was observed to have % 
entrapment efficiency, % drug release and % buoyancy of 68.33%, 
84.21% and 78.66% respectively. The statistical insignificance of the 
observed values for extra design checkpoint formulation (F10) was 
evaluated with the predicted value using Student’s t-test.  
It was found to non-significant with 95% confidence interval. This 
statistical insignificance of the difference between the predicted and 
observed responses of extra design checkpoint formulation not only 
validate the design adopted for optimization but also confirmed the 
usefulness of a polynomial equation in predicting the % entrapment 
efficiency, % drug release and % buoyancy.  
For the purpose of selecting the optimized formulation, the batch 
having maximum similarity when compared with the response 
variables of the extra design checkpoint batch and predicted values 
can be considered as the optimized batch.  
Table 3 showed that the observed values of the prepared batch (F6) 
were very close to the predicted values, with low percentage bias, 
suggesting that the optimized formulation was trustworthy and 
rational.
 
Table 3: Comparison of the observed and predicted values in the microsphere 
Responses variable Predicted value Observed value Bias % 
% Entrapment Efficiency 67.0957 67.63 -0.796 
% Drug Release 83.5238 83.52 0.0045 
% Buoyancy 79.6226 80.14 -0.649 
 
Drug release kinetics of optimized formulation  
The best selected in vitro drug release data of optimized formulation 
were fitted to various kinetics models such as zero order, first order, 
Higuchi and Peppas models. The highest regression coefficient (r2) 
values were obtained for Higuchi model (0.9979) followed by 
Korseymer-Peppas (0.9968), zero order (0.9364) and first order 
(0.9277) model using Microsoft excel software. It indicates diffusion 
to be the predominant mechanism of drug release from floating 
microballoons. Release mechanism was studied by Peppas Equation 
and value of slope or diffusion exponent (n) was determined. The 
value of diffusion exponent (n) was found to be 0.4956 that indicates 
non-Fickian or anomalous diffusion mechanism which leads to the 
conclusion that drug release mechanism indicates a combination of 
diffusion and spheres erosion. Zero order, first order, Higuchi and 
Korseymer-Peppas plots were shown in fig. 6 (a), (b), (c) and (d). 
 
 
(a)      (b) 
 
(c)      (d) 
Fig. 6: Drug release kinetic profile of optimized formulation F6 (a) zero order (b) first order (c) Higuchi (d) Korseymer peppas 
 
In vivo floating behavior study  
The in vivo floating behavior of microballoons loaded with barium 
sulphate was investigated by radiographic images (X-ray 
photographs) of rabbit’s stomach at periodic time intervals. The 
radiographs obtained at 0, 6 and 12 h are shown in fig. which 
indicates a uniform distribution of formulation over the gastric fluid 
and in vivo duration of floating for more than 12 h. 
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(a)    (b)   (c) 
Fig. 7: X-ray photograph of rabbit stomach: (a) without drug loaded microballoons (b) showing buoyancy of microballoons after 6 h (c) 
showing buoyancy of microballoons after 12 h 
 
Antiulcer activity  
In control group of animals, oral administration of absolute ethanol 
produced characteristic lesions in the glandular portion of rat 
stomach which appeared as elongated bands of thick, black and dark 
red lesions. The in vivo evaluation showed that animals treated with 
the optimized formulation, an optimized formulation with gallic acid 
and administered marketed brand of famotidine showed significant 
protection index of 83.26%, 89.04% and 76.09% respectively in 
comparison to control. Gallic acid is a well-known natural 
antioxidant that is basically a secondary polyphenolic metabolite. 
Floating microballoons of an optimized formulation containing gallic 
acid showed high ulcer protection index of 89.04% as compared to 
83.26% in the optimized formulation (F6). It may be due to the 
synergistic effect of famotidine with gallic acid. The combination of 
both may provide formulations with increased therapeutic effect. 
Macroscopical changes of ethanol-induced models are shown in fig. 
8(a), (b), (c) and (d). 
 
Table 4: Effect of various formulations on ethanol-induced gastric ulcer in rats 
Treatment Ulcer index % Ulcer Protection pH of gastric juice 
Control 4.1±1.25 - 1.9±0.62 
Optimized formulation 0.62±1.06* 83.26 4.3±0.39* 
Formulation with gallic acid 0.49±1.35* 89.04 4.8±0.81* 
Marketed brand of famotidine 0.98±10.83* 76.09 3.9±0.24* 
Values expressed as mean±SEM; *P<0.05 when compared with control group. 
 
           
(a)     (b)  
  
(c)      (d) 
Fig. 8: (a) Ulcerated control stomach (b) Optimized formulation treated stomach (c) Optimized formulation with gallic acid treated 
stomach (d) Famotidine marketed drug treated stomach 
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CONCLUSION 
Floating microballoons of famotidine with swellable hydrophilic 
polymer were successfully prepared using emulsion solvent 
diffusion method, by applying 32 factorial design. The prepared 
microballoons had a different size and the % entrapment efficiency 
of the drug by varying the formulation variables such as polymeric 
concentration and stirring rate. The prepared formulations were 
further evaluated and based on the results of in vitro drug release 
studies, % entrapment efficiency and % buoyancy, F6 was chosen as 
the best formulation.  
Optimized formulation (F6) followed Higuchi kinetics and the 
release mechanism was non Fickian diffusion (n=0.4956). SEM study 
showed porous nature and cavity formed in the microballoons. In 
vivo radiographic images were helpful to locate the position of 
floating microballoons in the gastrointestinal tract and also 
confirmed that the prepared microballoons were able to retain in 
the stomach for a prolonged period of time and sustained release of 
famotidine. Thus, the prepared buoyant microballoons may prove to 
be potential candidates for a multiple-unit delivery system for 
intragastric drug delivery. In vivo anti-ulcer evaluation showed that 
animals treated with the optimized formulation, an optimized 
formulation with the gallic acid of famotidine showed significant 
ulcer protection of 83.26% and 89.04% respectively in comparison 
to control. Thus, such floating microballoons of famotidine prove to 
be useful for the prolonged gastric residence of the drug, better 
bioavailability and anti-ulcer activity. 
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